Ratings Alfresa Holdings Corporation

Equities

2784

JP3126340003

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 EDT			5-day change	1st Jan Change
2,295 ^JPY	+4.20%		+6.84%	-4.24%

02-08	Alfresa Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	CI
02-08	Alfresa Holdings Corporation Provides Commemorative Dividend Guidance for the Fiscal Year Ending March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company appears to be poorly valued given its net asset value.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is highly valued given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
ALFRESA HOLDINGS CORPORATION	-4.24%	2.72B	C+
ABBOTT LABORATORIES	-2.31%	187B	C+
MEDTRONIC PLC	-3.20%	106B	C
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B	A
DEXCOM, INC.	+0.20%	49.45B	B-
CENCORA, INC.	+17.29%	48B	B-
HOYA CORPORATION	+4.06%	40.84B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B	B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B	A-
TERUMO CORPORATION	+12.96%	24.62B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes